BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Abbott Laboratories (ABT) Set to Consolidate India Operations


11/28/2012 7:25:11 AM

The $39-billion pharma giant Abbott Laboratories will consolidate India operations under a new leadership , as part of a plan to tap broad operational synergies between the three domestic units, said sources aware of the development. The New York-listed Abbott , which tops India's drug retail market after acquiring Ajay Piramal's domestic formulations business, will soon appoint a new chief executive who will oversee its $1 billion operations spread across three companies—Abbott India , Abbott Healthcare and Abbott True Care. The current heads of these three units—Rehan Khan, Sudharshan Jain and Rajendra Dhandhukia—will report into the new country chief. An internal memo from the global HQ about the impending changes has been communicated to the senior India leadership team. Abbott's proposed revamp is in sync with the single-CEO /country head management structure followed by other multinationals. The Illinois-based behemoth had 6.8% share of the domestic drug retail sales, ahead of the closest rivals CiplaBSE 2.53 % (5.1%) and RanbaxyBSE 1.06 % (4.6%). When contacted , an Abbott spokesperson declined to comment on the matter.



Abbott
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->